The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EHA 2019 | Myeloma XI subgroup analysis of KCRd induction by molecular risk

Jun 17, 2019

To view this video in other languages, please play the video and click on the settings icon. Click on “subtitles/CC”, followed by “auto translate”, and then select your chosen language from the drop-down menu.

At the 24th Congress of the European Hematology Association (EHA), Charlotte Pawlyn from the Institute of Cancer Research, London, UK, presents a subgroup analysis of carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone (KCRd) induction by molecular risk from the Myeloma XI study.

Dr. Pawlyn introduces the Myeloma XI trial which evaluated more than 4000 newly diagnosed transplant eligible patients with MM in 110 National Health Service (NHS) centers. The subgroup analysis of a patient population with genetic mutations showed similarly superior progression-free survival (PFS) with quadruplet, rather than triplet, therapy.

Myeloma XI subgroup analysis of KCRd induction by molecular risk